The cannabinoid CB1 receptor antagonist SR 141716A reverses the antiemetic and motor depressant actions of WIN 55, 212-2.

No abstract is available for this paper.

• Publication year

  2001

• Venue

  European Journal of Pharmacology

• Publication date

  2001-10-26

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/S0014-2999(01)01355-3PMID 11698062
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Delta-9-tetrahydrocannabinol differentially suppresses cisplatin-induced emesis and indices of motor function via cannabinoid CB(1) receptors in the least shrew.

  2001cited by this paper
• Δ9-Tetrahydrocannabinol and Synthetic Cannabinoids Prevent Emesis Produced by the Cannabinoid CB1 Receptor Antagonist/Inverse Agonist SR 141716A

  2001cited by this paper
• Activational role of cannabinoids on movement.

  2000cited by this paper
• The 5-HT3 agent N-(3-chlorophenyl)guanidine (MD-354) serves as a discriminative stimulus in rats and displays partial agonist character in a shrew emesis assay

  2000cited by this paper
• Cannabinoid agonist signal transduction in rat brain: comparison of cannabinoid agonists in receptor binding, G-protein activation, and adenylyl cyclase inhibition.

  2000cited by this paper
• Delta9-tetrahydrocannabinol inhibits gastric motility in the rat through cannabinoid CB1 receptors.

  1999cited by this paper
• HU-308: a specific agonist for CB(2), a peripheral cannabinoid receptor.

  1999cited by this paper
• Defaecation, intestinal fluid accumulation and motility in rodents: implications of cannabinoid CB1 receptors

  1999cited by this paper
• The motivation for beer in rats: effects of ritanserin, naloxone and SR 141716

  1999cited by this paper
• The role of D2 and D3 dopamine receptors in the mediation of emesis in Cryptotis parva (the least shrew)

  1999cited by this paper
• Large Receptor Reserve for Cannabinoid Actions in the Central Nervous System 1

  1999cited by this paper
• Motor actions of cannabinoids in the basal ganglia output nuclei.

  1999cited by this paper
• Blockade of cannabinoid (CB1) receptors by SR 141716 selectively antagonizes drug-induced reinstatement of exploratory behaviour in gerbils

  1999cited by this paper
• Cannabimimetic activity in rats and pigeons of HU 210, a potent antiemetic drug.

  1999cited by this paper
• SR 141716A, a CB1 cannabinoid receptor antagonist, potentiates the locomotor stimulant effects of amphetamine and apomorphine.

  1999cited by this paper
• Cannabis and Cannabinoids: Pharmacology and Rationale for Clinical Use

  1999cited by this paper
• Cannabinoids and the Control of Chemotherapy-Induced Nausea and Vomiting

  1999cited by this paper
• Marijuana and Medicine

  1999cited by this paper
• Large receptor reserve for cannabinoid actions in the central nervous system.

  1999cited by this paper
• Serotonin 5-HT3 receptor antagonists prevent cisplatin-induced emesis in Cryptotis parva: a new experimental model of emesis

  1998cited by this paper
• Cannabinoid modulation of intestinal propulsion in mice.

  1998cited by this paper
• Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system.

  1998cited by this paper
• Biphasic effects of anandamide.

  1998cited by this paper
• SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor.

  1998cited by this paper
• Physiology of Chemotherapy-Induced Emesis and Antiemetic Therapy

  1997cited by this paper
• The selective cannabinoid antagonist SR 141716A blocks cannabinoid-induced antinociception in rats.

  1997cited by this paper
• Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain.

  1997cited by this paper
• Clobenzorex: evidence for amphetamine-like behavioral actions.

  1997cited by this paper
• Medicinal Applications of Delta-9-Tetrahydrocannabinol and Marijuana

  1997cited by this paper
• Inhibition of intestinal motility by anandamide, an endogenous cannabinoid.

  1997cited by this paper
• In vivo characterization of a specific cannabinoid receptor antagonist (SR141716A): inhibition of delta 9-tetrahydrocannabinol-induced responses and apparent agonist activity.

  1996cited by this paper
• Further evidence for the presence of cannabinoid CB1 receptors in guinea‐pig small intestine

  1996cited by this paper
• Extrapyramidal effects of methanandamide, an analog of anandamide, the endogenous CB1 receptor ligand.

  1996cited by this paper
• Mechanisms of chemotherapy/radiotherapy-induced emesis in animal models.

  1996cited by this paper
• An efficient new cannabinoid antiemetic in pediatric oncology.

  1995cited by this paper
• Pharmacological characterization of three novel cannabinoid receptor agonists in the mouse isolated vas deferens.

  1995cited by this paper
• SR141716A, a potent and selective antagonist of the brain cannabinoid receptor

  1994cited by this paper
• The ACTH(4-9) analog Org2766 modulates the behavioral changes induced by NMDA and the NMDA receptor antagonist AP5

  1994cited by this paper
• Cannabinoids and appetite stimulation.

  1994cited by this paper
• Structural requirements for cannabinoid receptor probes

  1994cited by this paper
• Molecular characterization of a peripheral receptor for cannabinoids

  1993cited by this paper
• SPONTANEOUS LOCOMOTOR ACTIVITY IN ARCTIC CHARR MEASURED BY A COMPUTERIZED IMAGING TECHNIQUE: ROLE OF BRAIN SEROTONERGIC ACTIVITY

  1993cited by this paper
• Pharmacological agents affecting emesis. A review (Part I).

  1992cited by this paper
• Aminoalkylindole analogs: cannabimimetic activity of a class of compounds structurally distinct from delta 9-tetrahydrocannabinol.

  1992cited by this paper
• Distribution of neuronal cannabinoid receptor in the adult rat brain: a comparative receptor binding radioautography and in situ hybridization histochemistry.

  1992cited by this paper
• Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study

  1991cited by this paper
• The Natural History of Shrews

  1991cited by this paper
• Structure of a cannabinoid receptor and functional expression of the cloned cDNA

  1990cited by this paper
• Inhibition of cisplatin-induced emesis in the pigeon by a non-psychotropic synthetic cannabinoid.

  1989cited by this paper
• Psychoactive cannabinoids reduce gastrointestinal propulsion and motility in rodents.

  1989cited by this paper
• The medicinal uses of cannabis and its constituents

  1989cited by this paper
• Nabilone versus prochlorperazine for control of cancer chemotherapy-induced emesis in children: a double-blind, crossover trial.

  1987cited by this paper
• Nabilone: an alternative antiemetic for cancer chemotherapy.

  1986cited by this paper
• ANTIEMETIC PROPERTIES AND PLASMA CONCENTRATIONS OF DELTA-9-TETRAHYDROCANNABINOL AGAINST CISPLATIN VOMITING IN CATS*

  1984cited by this paper
• Antiemetic therapy: a review of recent studies and a report of a random assignment trial comparing metoclopramide with delta-9-tetrahydrocannabinol.

  1984cited by this paper
• The cannabinoids: chemical, pharmacologic, and therapeutic aspects.

  1984cited by this paper
• Δ9‐Tetrahydrocannabinol As An Antiemetic For Patients Receiving Cancer Chemotherapy. A Pilot Study

  1981cited by this paper
• Antiemetic Effect of Δ9‐Tetrahydrocannabinol in Chemotherapy‐Associated Nausea and Emesis As Compared to Placebo and Compazine

  1981cited by this paper
• Antiemetics in patients receiving chemotherapy for cancer: a randomized comparison of delta-9-tetrahydrocannabinol and prochlorperazine.

  1980cited by this paper
• delta 9-Tetrahydrocannabinol for refractory vomiting induced by cancer chemotherapy.

  1980cited by this paper
• Delta-9-tetrahydrocannabinol as an antiemetic for patients receiving cancer chemotherapy. A comparison with prochlorperazine and a placebo.

  1979cited by this paper
• Delata-9-tetrahydrocannabinol as an antiemetic in cancer patients receiving high-dose methotrexate. A prospective, randomized evaluation.

  1979cited by this paper
• Suppression of Cancer Chemotherapy-Induced Vomiting in the Cat by Nabilone, a Synthetic Cannabinoid 1

  1979cited by this paper
• Lack of antiemetic effects of delta9-tetrahydrocannabinol in apomorphine-induced emesis in the dog.

  1978cited by this paper
• Antiemetic effect of delta-9-tetrahydrocannabinol in patients receiving cancer chemotherapy.

  1975cited by this paper
• The analgesic properties of delta‐9‐tetrahydrocannabinol and codeine

  1975cited by this paper
• The mechanisms of action of L-dopa in Parkinson's disease.

  1974cited by this paper
• Marihuana on locomotor activity: biphasic effect and tolerance development.

  1972cited by this paper
• Marihuana on locomotor activity: biphasic effect and tolerance development.

  1972cited by this paper
• Structure activity relationship of four tetrahydrocannabinols and the pharmacological activity of five semi-purified extracts of Cannabis sativa

  1970cited by this paper
• Studies on the pharmacology and acute toxicity of compounds with marihuana activity.

  1946cited by this paper

• The Cannabinoid CB1 Receptor Inverse Agonist/Antagonist SR141716A Activates the Adenylate Cyclase/PKA Signaling Pathway Among Other Intracellular Emetic Signals to Evoke Vomiting in Least Shrews (Cryptotis parva)

  2025cites this paper
• Screening study of anti-emetics to improve GDF15-induced malaise and anorexia: Implications for emesis control.

  2023cites this paper
• Evidence for Bell-Shaped Dose-Response Emetic Effects of Temsirolimus and Analogs: The Broad-Spectrum Antiemetic Efficacy of a Large Dose of Temsirolimus Against Diverse Emetogens in the Least Shrew (Cryptotis parva)

  2022cites this paper
• Cannabinoid drugs against chemotherapy-induced adverse effects: focus on nausea/vomiting, peripheral neuropathy and chemofog in animal models

  2022cites this paper
• Cannabis sativa: Interdisciplinary Strategies and Avenues for Medical and Commercial Progression Outside of CBD and THC

  2021cites this paper
• Opportunities for cannabis in supportive care in cancer

  2019cites this paper
• Role of chronic cannabis use: Cyclic vomiting syndrome vs cannabinoid hyperemesis syndrome

  2019influential citation
• Δ9-THC and related cannabinoids suppress substance P- induced neurokinin NK1-receptor-mediated vomiting via activation of cannabinoid CB1 receptor.

  2019cites this paper
• Cannabis and Its Secondary Metabolites: Their Use as Therapeutic Drugs, Toxicological Aspects, and Analytical Determination

  2019cites this paper
• Perioperative care of cannabis users: A comprehensive review of pharmacological and anesthetic considerations.

  2019cites this paper
• Functional Emesis.

  2019influential citation
• Conditioned gaping produced by high dose &Dgr;9‐tetrahydracannabinol: Dysregulation of the hypothalamic endocannabinoid system

  2018cites this paper
• Reward-related limbic memory and stimulation of the cannabinoid system: An upgrade in value attribution?

  2018influential citation
• Strain Differences in Cannabinoid-Reinforced Lever Press Discrimination

  2017cites this paper
• Cannabinoid Hyperemesis Syndrome: Public Health Implications and a Novel Model Treatment Guideline

  2017cites this paper
• The Impact of Cannabinoids on Motor Activity and Neurochemical Correlates

  2017cites this paper
• Clinical Approach to the Heavy Cannabis User in the Age of Medical Marijuana

  2016cites this paper
• Cannabinoid Hyperemesis Syndrome: Diagnosis, Pathophysiology, and Treatment—a Systematic Review

  2016cites this paper
• Cannabinoid 2 (CB2) receptor agonism reduces lithium chloride-induced vomiting in Suncus murinus and nausea-induced conditioned gaping in rats.

  2016cites this paper
• Therapeutic potential of cannabis-related drugs.

  2016cites this paper
• Anti-Obesity Effect of the CB2 Receptor Agonist JWH-015 in Diet-Induced Obese Mice

  2015cites this paper
• Behavioral and Neurochemical Changes in Mesostriatal Dopaminergic Regions of the Rat after Chronic Administration of the Cannabinoid Receptor Agonist WIN55,212-2

  2015cites this paper
• Endocannabinoid Regulation of Nausea and Emesis: The Role of 2-arachidonoylglycerol in LiCl-induced Vomiting in Suncus Murinus and Conditioned Gaping in Rats

  2015cites this paper
• Regulation of nausea and vomiting by cannabinoids and the endocannabinoid system.

  2014influential citation
• Cannabinoids and the brain: New hopes for new therapies

  2014cites this paper
• Cannabinoids negatively modulate striatal glutamate and dopamine release and behavioural output of acute D-amphetamine.

  2014cites this paper
• THC-MEDIATED INDUCTION OF ΔFOSB AND ITS MODULATION OF CB1R SIGNALING AND ADAPTATION

  2013cites this paper
• Do initial responses to drugs predict future use or abuse?

  2012cites this paper
• The anti‐nausea effects of CB1 agonists are mediated by an action at the visceral insular cortex

  2012cites this paper
• Changes in the Endocannabinoid system in the Brain Following Bilateral Vestibular Damage

  2011cites this paper
• Regulation of nausea and vomiting by cannabinoids

  2011cites this paper
• The cannabinoid WIN 55,212‐2‐mediated protection of dentate gyrus granule cells is driven by CB1 receptors and modulated by TRPA1 and Cav2.2 channels

  2011cites this paper
• Alternative targets within the endocannabinoid system for future treatment of gastrointestinal diseases.

  2011cites this paper
• Mechanisms of Broad-Spectrum Antiemetic Efficacy of Cannabinoids against Chemotherapy-Induced Acute and Delayed Vomiting

  2010cites this paper
• Inverse agonism of cannabinoid CB1 receptors potentiates LiCl‐induced nausea in the conditioned gaping model in rats

  2010cites this paper
• Individual differences in the effects of cannabinoids on motor activity, dopaminergic activity and DARPP-32 phosphorylation in distinct regions of the brain.

  2010cites this paper
• Targeting the endocannabinoid system for gastrointestinal diseases: future therapeutic strategies

  2010influential citation
• Evidence for a re-evaluation of the neurochemical and anatomical bases of chemotherapy-induced vomiting.

  2009cites this paper
• Therapeutic Applications for Agents that Act at CB1 and CB2 Receptors

  2009cites this paper
• 1. Efecto del envejecimiento en la estructura y funcionalidad del plexo mientérico de íleon de cobayo. 2. Efecto de los cannabinoides en las alteraciones causadas por el tratamiento crónico con cisplatino en rata.

  2009cites this paper
• The CB1 receptor agonist, WIN 55,212-2, dose-dependently disrupts object recognition memory in adult rats.

  2009cites this paper
• Intrinsic effects of AM4113, a putative neutral CB1 receptor selective antagonist, on open-field behaviors in rats.

  2008cites this paper
• Differential effects of neurotoxin-induced lesions of the basolateral amygdala and central nucleus of the amygdala on lithium-induced conditioned disgust reactions and conditioned taste avoidance.

  2008cites this paper
• Enhancement of endocannabinoid neurotransmission through CB1 cannabinoid receptors counteracts the reinforcing and psychostimulant effects of cocaine.

  2008cites this paper
• Cannabinoids in the Management of Nausea and Vomiting

  2008cites this paper
• Bidirectional cannabinoid modulation of social behavior in adolescent rats

  2008cites this paper
• The effects of cannabidiol and tetrahydrocannabinol on motion-induced emesis in Suncus murinus.

  2008cites this paper
• Strain and schedule-dependent differences in the acquisition, maintenance and extinction of intravenous cannabinoid self-administration in rats.

  2007cites this paper
• WIN 55,212-2 prevents mechanical allodynia but not alterations in feeding behaviour induced by chronic cisplatin in the rat.

  2007cites this paper
• Arvanil, anandamide and N‐arachidonoyl‐dopamine (NADA) inhibit emesis through cannabinoid CB1 and vanilloid TRPV1 receptors in the ferret

  2007cites this paper
• Receptor mechanism and antiemetic activity of structurally-diverse cannabinoids against radiation-induced emesis in the least shrew.

  2007cites this paper
• Effect of Exposure to Lithium-Paired or Amphetamine-Paired Saccharin Solution on Open Arm Avoidance in an Elevated Plus Maze.

  2006cites this paper
• AM 251 produces sustained reductions in food intake and body weight that are resistant to tolerance and conditioned taste aversion

  2006cites this paper
• Modulation of paraoxon toxicity by the cannabinoid receptor agonist WIN 55,212-2.

  2006cites this paper
• Effects of the CB1R agonist WIN-55,212-2 and the CB1R antagonists SR-141716 and AM-1387: open-field examination in rats.

  2006cites this paper
• The role of endocannabinoid transmission in cocaine addiction.

  2005cites this paper
• Endocannabinoids in the regulation of appetite and body weight

  2005cites this paper
• Delta-9-tetrahydrocannabinol differentially suppresses emesis versus enhanced locomotor activity produced by chemically diverse dopamine D2/D3 receptor agonists in the least shrew (Cryptotis parva).

  2005cites this paper
• Cannabinoids and the digestive tract.

  2005cites this paper
• Cannabinoids: effects on vomiting and nausea in animal models

  2005cites this paper
• Endocannabinoids and Gastrointestinal Function

  2005cites this paper
• Ondansetron and Delta-9-tetrahydrocannabinol interfere with the establishment of lithium-induced conditioned taste avoidance in the house musk shrew (Suncus murinus).

  2005cites this paper
• Cannabinoid - 1 Rezeptoren (CB 1 ) beeinflussen die Motilität des Dünndarms von Maus und Ratte - Untersuchungen zum peristaltischen Reflex und Dünndarmtransit

  2005cites this paper
• Cisplatin increases brain 2-arachidonoylglycerol (2-AG) and concomitantly reduces intestinal 2-AG and anandamide levels in the least shrew.

  2005cites this paper
• Effects of the cannabinoid receptor agonist WIN 55,212-2 on operant behavior and locomotor activity in rats.

  2005cites this paper
• [Review of cannabinoids in the treatment of nausea and vomiting].

  2004cites this paper
• Central and peripheral mechanisms contribute to the antiemetic actions of delta-9-tetrahydrocannabinol against 5-hydroxytryptophan-induced emesis.

  2004cites this paper
• The gastrointestinal pharmacology of cannabinoids: an update.

  2004cites this paper
• A comparative analysis of the potential of cannabinoids and ondansetron to suppress cisplatin-induced emesis in the Suncus murinus (house musk shrew)

  2004influential citation
• Involvement of cannabinoid receptors in gut motility and visceral perception

  2004cites this paper
• Cannabinoide in der Behandlung von Übelkeit und Erbrechen

  2004cites this paper
• Effects of cannabinoids on lithium-induced conditioned rejection reactions in a rat model of nausea

  2003cites this paper
• Effect of cannabinoids on lithium-induced vomiting in the Suncus murinus (house musk shrew)

  2003influential citation
• Antiemetic and motor-depressive actions of CP55,940: cannabinoid CB1 receptor characterization, distribution, and G-protein activation.

  2003cites this paper
• Cannabinoid agonists and antagonists modulate lithium-induced conditioned gaping in rats

  2003cites this paper
• Behaviorally active doses of the CB1 receptor antagonist SR 141716A increase brain serotonin and dopamine levels and turnover.

  2003cites this paper
• Therapeutic Potential of Cannabinoids in CNS Disease

  2003cites this paper
• Cannabinoids for gastrointestinal diseases: potential therapeutic applications

  2003cites this paper
• Cannabidiol, a non‐psychoactive component of cannabis and its synthetic dimethylheptyl homolog suppress nausea in an experimental model with rats

  2002cites this paper
• For online use by the Drug Policy Alliance only

  2002cites this paper
• Interactions between the CB1 receptor agonist Delta 9-THC and the CB1 receptor antagonist SR-141716 in rats: open-field revisited.

  2002cites this paper
• Cannabinoid receptor agonism inhibits transient lower esophageal sphincter relaxations and reflux in dogs.

  2002cites this paper
• The potent emetogenic effects of the endocannabinoid, 2-AG (2-arachidonoylglycerol) are blocked by delta(9)-tetrahydrocannabinol and other cannnabinoids.

  2002cites this paper
• Endocannabinoids as physiological regulators of colonic propulsion in mice.

  2002cites this paper
• The gastrointestinal pharmacology of cannabinoids.

  2001cites this paper